FibroGenesis, is a regenerative medicine company developing an innovative cure for chronic diseases using fibroblasts. There are only two cell types in the human body which can regenerate tissue and organs. Those cells are stem cells and fibroblasts. Our studies have proven fibroblasts to be more effective and more potent than stem cells in regeneration of tissue and reduction in inflammation.
Fibroblasts comprise the main cell type of connective tissue, possessing a spindle-shaped morphology, whose classical function has historically been to produce extracellular matrix responsible for maintaining structural integrity of tissue. Fibroblasts also play an important role in proliferative phase of wound healing, resulting in deposition of extracellular matrix.
We are developing treatment options for multiple disease pathways using fibroblasts. Our studies have shown fibroblasts to be more effective than stem cells in the treatment of Cancer, Diabetes, Multiple Sclerosis, Parkinson's, Colitis and many other chronic diseases. As our clinical work moves into human trials, we believe fibroblasts will prove allogenic cell therapy using fibroblasts as the most promising opportunity to cure chronic diseases modern medicine has seen in many generations.
Please take a moment to review the many peer reviewed articles in our Technology Page and then explore our 260+ patents in our Intellectual Property Page. Finally, our Pipeline Page can show you the various disease pathways we believe fibroblasts can impact.
Currently, FibroGenesis holds 260+ U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson’s, Chronic Traumatic Encephalopathy, Colitis, Cancer, Diabetes, Liver Failure and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.
February 17. 2021
FibroGenesis induces cancer regression using fibroblasts
December 10, 2020
FibroGenesis Uses Apple Watch to Extend Its Clinical Monitoring of COVID-19 Patients
November 10, 2020
FibroGenesis Reaches Milestone to File Its 250th Patent
October 1, 2020
FibroGenesis Announces Collaboration Agreement with Brazilian Biotech R4D Read More
September 28, 2020
FibroGenesis Announces Manufacturing Agreement Read More
August 12, 2020
FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Read More
July 21, 2020
FibroGenesis Reduces COVID-19 Lung Scarring in Animal Model Read More
July 1, 2020
FibroGenesis Identifies Mechanism Responsible for Blocking COVID-19 Lung Inflammation Read More